Clinical Perspectives in Oncology Nursing: Management and Treatment of Multiple Myeloma
Provided by:
Support for this activity has been made possible through educational grants from Celgene, Amgen and Takeda Oncology.
*** This activity is no longer available for credit ***
Release date: 1/3/2018
Expiration date: 1/3/2019
Estimated time to complete: 1.5 hours
Education Need
Several clinical practice gaps have been identified that contribute to less than optimal care for patients with multiple myeloma (MM) and which may be addressed through continuing education. In this time of multiple recent FDA approvals of new medications for the treatment of MM, a new burden is placed upon clinicians who care for these patients to become educated on these novel drugs’ benefits and side effects profiles and to integrate them into clinical practice. It is crucial to achieving optimum outcomes for patients with MM that they are offered access to the latest innovations in treatment. However, for this to happen, the entire care team—including oncology nurses and advanced practice nurses—need to be fully apprised of new information and transfer their learnings to patients as well as other members of the interdisciplinary care team. These new medications are used in combination therapy, which increases the complexity of care, and oncology nursing professionals require updates on guideline recommendations for best treatment strategies. In addition, supportive care for conditions caused by the disease or its treatment is not consistently provided. Finally, patients often are not given the option of participating in clinical trials because clinicians may not be fully apprised of current trials and the benefits of patient participation. This activity has been designed to address these gaps in order that oncology nursing professionals who care for patients with MM may achieve the best outcomes possible.
Activity Faculty
Patricia A. Mangan, MSN, CRNP
Nurse Lead of the Hematologic Malignancies and Stem Cell Transplant Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Target Audience
This educational activity is designed to meet the needs of oncology nursing professionals involved in the care of patients with multiple myeloma.
Learning Objectives/Learning Outcomes
After participating in the activity, learners should be better able to:
- Explain the benefit and risk profiles of recently approved treatments for the management of multiple myeloma, and which patients might benefit from these medications.
- Outline recommended combination therapies for different stages and types of MM.
- Describe conditions that frequently arise in patients with MM as a result of the disease and/or treatment, and how supportive care can be best provided to address them.
- Employ communication strategies that will help convey the benefits and burdens of clinical trial participation to patients with MM.
Accreditation and Credit Designation
American Academy of CME, Inc is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
American Academy of CME, Inc. designates this educational activity for 1.0 contact hours (.9 pharmacotherapeutic contact hours).
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Faculty Disclosure
Ms. Mangan discloses the following:
- Serves on the Advisory Board (for scientific information) - Kite Pharma
- Serves on the Promotional Speakers Bureau - Celgene, Takeda, Amgen
This educational activity may contain discussion of published and/or investigational uses of agents not indicated by the FDA. Faculty have been asked to disclose off-label and/or investigational uses if they are mentioned.
- Ms. Mangan has stated there will be off-label discussion of PD1-inhibitors.
Planning Committee
- John JD Juchniewicz, MCIS, CHCP; Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner; Paul Miniter, MS; and Wendy Gloffke, PhD – American Academy of CME: No relevant financial relationships with any commercial interests.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, or American Nurses Credentialing Center’s Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
How to Participate
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives/learning outcomes and disclosure statements, as well as the content of the activity.
To receive CNE credit for your participation, please return to this page and use the link below to complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.
*** This activity is no longer available for credit ***
Hardware/Software Requirements
Participants will need to have QuickTime, Windows Media Player, or VLC to view the program.
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm
Contact
For any questions, please contact: [email protected]
Copyright
© 2018. This CNE-certified activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).